SMARCA2 and cancer: Similarly, HDAC inhibitors have been proven to be effective in restoring the expression of the mutually exclusive, catalytically active subunits of the SWI/SNF complex, BRM and BRG1, which are silenced in nearly 20% of all cancers [92–94].